Last reviewed · How we verify
Normal Medication Positive Control
At a glance
| Generic name | Normal Medication Positive Control |
|---|---|
| Sponsor | Endocrine Research Society |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain (PHASE2)
- A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer (NA)
- Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- Evaluation of the Effectiveness of a Protocol for the Management of Female Functional Urinary Signs (NA)
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (PHASE3)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Normal Medication Positive Control CI brief — competitive landscape report
- Normal Medication Positive Control updates RSS · CI watch RSS
- Endocrine Research Society portfolio CI